The estimated Net Worth of Jay M Moyes is at least $1.34 Million dollars as of 13 June 2024. Mr. Moyes owns over 22,000 units of Puma Biotechnology Inc stock worth over $53,305 and over the last 22 years he sold PBYI stock worth over $926,818. In addition, he makes $357,201 as Lead Independent Director at Puma Biotechnology Inc.
Jay has made over 25 trades of the Puma Biotechnology Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 22,000 units of PBYI stock worth $73,480 on 13 June 2024.
The largest trade he's ever made was exercising 28,196 units of Puma Biotechnology Inc stock on 13 September 2007 worth over $286,471. On average, Jay trades about 4,725 units every 112 days since 2003. As of 13 June 2024 he still owns at least 21,322 units of Puma Biotechnology Inc stock.
You can see the complete history of Mr. Moyes stock trades at the bottom of the page.
Jay M. Moyes CPA serves as Lead Independent Director of the Company. Mr. Moyes has served as the Chief Financial Officer of Sera Prognostics, Inc., a private clinical-stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, since March 2020. Mr. Moyes has been a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, since August 2017. He has been a member of the board of directors of Biocardia, Inc., a publicly held cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as a member of the board of directors of Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019. Mr. Moyes was a director of Integrated Diagnostics, Inc., a privately held molecular diagnostics company from March 2011 to November 2016. Mr. Moyes was a member of the board of directors of Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017 and Amedica Corporation, a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014. From May 2008 through July 2009, Mr. Moyes served as the Chief Financial Officer of XDx (now CareDx), Inc., a privately held molecular diagnostics company. Prior to that, Mr. Moyes served as the Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007, and as its Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certi
As the Lead Independent Director of Puma Biotechnology Inc, the total compensation of Jay Moyes at Puma Biotechnology Inc is $357,201. There are 11 executives at Puma Biotechnology Inc getting paid more, with Alan H. Auerbach having the highest compensation of $5,693,423.
Jay Moyes is 66, he's been the Lead Independent Director of Puma Biotechnology Inc since 2018. There are no older and 15 younger executives at Puma Biotechnology Inc.
Jay's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES, CA, 90024.
Over the last 13 years, insiders at Puma Biotechnology Inc have traded over $168,440,369 worth of Puma Biotechnology Inc stock and bought 2,655,298 units worth $48,866,148 . The most active insiders traders include Capital Partners Gp, L.L.C...., Steven Lo, and Troy Edward Wilson. On average, Puma Biotechnology Inc executives and independent directors trade stock every 18 days with the average trade being worth of $60,225. The most recent stock trade was executed by Michael Patrick Miller on 12 August 2024, trading 23,358 units of PBYI stock currently worth $81,519.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
Puma Biotechnology Inc executives and other stock owners filed with the SEC include: